These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24872311)

  • 61. Development of polycystic ovary syndrome: involvement of genetic and environmental factors.
    Franks S; McCarthy MI; Hardy K
    Int J Androl; 2006 Feb; 29(1):278-85; discussion 286-90. PubMed ID: 16390494
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Polycystic ovary syndrome and type 2 diabetes mellitus.
    De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
    Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of obesity and adiposity in polycystic ovary syndrome.
    Diamanti-Kandarakis E
    Int J Obes (Lond); 2007 Nov; 31 Suppl 2():S8-13; discussion S31-2. PubMed ID: 17968437
    [TBL] [Abstract][Full Text] [Related]  

  • 64. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Changes in the PCOS phenotype with age.
    Hsu MI
    Steroids; 2013 Aug; 78(8):761-6. PubMed ID: 23624031
    [TBL] [Abstract][Full Text] [Related]  

  • 67. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome.
    Hutchison SK; Stepto NK; Harrison CL; Moran LJ; Strauss BJ; Teede HJ
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E48-56. PubMed ID: 20926534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Insulin resistance is not conserved in myotubes established from women with PCOS.
    Eriksen M; Pørneki AD; Skov V; Burns JS; Beck-Nielsen H; Glintborg D; Gaster M
    PLoS One; 2010 Dec; 5(12):e14469. PubMed ID: 21209881
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.
    Dunaif A; Xia J; Book CB; Schenker E; Tang Z
    J Clin Invest; 1995 Aug; 96(2):801-10. PubMed ID: 7635975
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Polycystic ovary syndrome: physiopathology review].
    Fux Otta C; Fiol de Cuneo M; Szafryk de Mereshian P
    Rev Fac Cien Med Univ Nac Cordoba; 2013; 70(1):27-30. PubMed ID: 23920100
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS).
    Valsamakis G; Lois K; Kumar S; Mastorakos G
    Hormones (Athens); 2013; 12(3):363-78. PubMed ID: 24121378
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development of obesity and polycystic ovary syndrome in adolescents.
    Vilmann LS; Thisted E; Baker JL; Holm JC
    Horm Res Paediatr; 2012; 78(5-6):269-78. PubMed ID: 23208318
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Genetic aspects of polycystic ovary syndrome].
    Jakubowski L
    Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Polycystic ovary syndrome: from physiopathology to therapy].
    Vicino M; Loizzi V; Scardigno D; Selvaggi L
    Minerva Ginecol; 2006 Feb; 58(1):55-67. PubMed ID: 16498371
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Insulin sensitizers in polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Front Horm Res; 2013; 40():83-102. PubMed ID: 24002407
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adipose tissue dysfunction in polycystic ovary syndrome.
    Villa J; Pratley RE
    Curr Diab Rep; 2011 Jun; 11(3):179-84. PubMed ID: 21424395
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Associations of Vitamin D with Inter- and Intra-Muscular Adipose Tissue and Insulin Resistance in Women with and without Polycystic Ovary Syndrome.
    Scott D; Joham A; Teede H; Gibson-Helm M; Harrison C; Cassar S; Hutchison S; Ebeling PR; Stepto N; de Courten B
    Nutrients; 2016 Nov; 8(12):. PubMed ID: 27916865
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
    Ortiz-Flores AE; Luque-Ramírez M; Escobar-Morreale HF
    Expert Opin Pharmacother; 2018 Dec; 19(17):1915-1926. PubMed ID: 30289728
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Polycystic ovary syndrome and female reproduction.
    Elghblawi E
    Br J Nurs; 2007 Oct 11-24; 16(18):1118-21. PubMed ID: 18073681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.